FDA clears Artemis' image-guided breast biopsy device:
This article was originally published in Clinica
Artemis Medical has received US FDA 510(k) clearance for its MiniTome breast biopsy system. The device can localise and immobilise target breast tissue more precisely than current techniques, Artemis claims. It can also accurately cut and remove a large, architecturally intact sample through a minimally invasive incision. An intact sample provides a more definitive diagnosis, explains the Hayward, California firm. Around 1.4 million breast biopsies are performed in the US annually, over 50% of which use open surgical techniques in order to acquire a large intact sample, notes the company.
You may also be interested in...
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.